首页> 外文会议>International Conference on Healthcare Informatics >Discovering Drug-Drug Interactions and Associated Adverse Drug Reactions with Triad Prediction in Heterogeneous Healthcare Networks
【24h】

Discovering Drug-Drug Interactions and Associated Adverse Drug Reactions with Triad Prediction in Heterogeneous Healthcare Networks

机译:发现药物 - 药物相互作用和相关的非均相医疗网络中三合会预测的相关不良药物反应

获取原文

摘要

Drug-drug interactions (DDIs) are of great importance in drug safety. Currently, DDI signal detection mainly depends on post-marketing surveillance. Various data sources have been used by researchers for DDI detection such as spontaneous reporting system, electronic health records, Pharmacological Databases, and biomedical literatures. However, these data sources are limited by either high underreporting ratio, access difficulty, or long publication cycle. In this work, we propose to utilize consumer-contributedcontents from online health communities, a publicly available, mountainous, and timely data source, for identifying DDI signals and association adverse drug reactions (ADRs). Specifically, we first construct a heterogeneous healthcare network, extract different topological types of Drug-Drug-ADR triad, explore node-based, link-based, and triad-based features, and then formulate the signal detection as a supervised learning problem. The experiment results show that our proposed techniques are effective in detecting DDI signals and associated ADRs at the same time.
机译:药物 - 药物相互作用(DDIS)在药物安全方面具有重要意义。目前,DDI信号检测主要取决于营销后监测。研究人员用于DDI检测的各种数据源,例如自发报告系统,电子健康记录,药理数据库和生物医学文献。然而,这些数据源受到高途径比率,访问难度或长发布周期的限制。在这项工作中,我们建议利用来自在线健康社区的消费者贡献,公开,山区和及时数据源,用于识别DDI信号和关联不良药物(ADR)。具体而言,我们首先构建异构医疗保健网络,提取不同拓扑类型的药物 - 药物 - ADR三合会,探索基于节点,基于链接的和三合会的特征,然后将信号检测作为监督的学习问题。实验结果表明,该技术是有效的,同时检测DDI信号和相关的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号